GM-CSF/CSF2 Protein, Mouse, Recombinant

Name: GM-CSF/CSF2 Protein, Mouse, Recombinant
Brand: TargetMol
SKU: TMPY-04114
Price: 43 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: MGI-IGM, Gm-CSf, GMCSF, Csfgm, colony stimulating factor 2 (granulocyte-macrophage)) Copy Product Info

Synonyms: MGI-IGM, Gm-CSf, GMCSF, Csfgm, colony stimulating factor 2 (granulocyte-macrophage)

Catalog No. TMPY-04114 Copy Product Info

Purity: 96.1%

GM-CSF/CSF2 Protein, Mouse, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 14.1 kDa and the accession number is P01587.

Pack Size	Price	USA Stock	Global Stock
5 µg	$43	-	In Stock
10 µg	$66	-	In Stock
20 µg	$106	In Stock	In Stock
50 µg	$189	-	In Stock
100 µg	$296	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:96.1%

Appearance:Lyophilized powder

Color:White

Resource Download

COA User Guide of Recombinant Proteins

Product Introduction

Bioactivity

Bioactivity	Measured in a cell proliferation assay using FDC-P1 cells. The ED50 for this effect is typically 0.01-0.04 ng/mL.
Description	GM-CSF/CSF2 Protein, Mouse, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 14.1 kDa and the accession number is P01587.
Species	Mouse
Expression System	HEK293 Cells
Tag	Tag Free
Accession Number	P01587
Construction	A DNA sequence encoding the mouse CSF2 (P01587) (Met1-Lys141) was expressed. Predicted N terminal: Ala 18
Protein Purity	> 95 % as determined by SDS-PAGE
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstituted with sterile deionized water to 0.25 mg/mL.
Synonyms	MGI-IGM, Gm-CSf, GMCSF, Csfgm, colony stimulating factor 2 (granulocyte-macrophage)
Research Background	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

Chemical Properties

Molecular Weight

14.1 kDa (predicted); 20.7 kDa (reducing conditions)

Storage & Solubility Information

Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.